Introduction {#s1}
============

Globally, in 2018, there were an estimated 570 000 new cases of cervical cancer and 311 000 deaths as a result of cervical cancer.[@R1] Human papillomavirus (HPV) infection is estimated to contribute to 4.5% of all cancers worldwide. Specifically, over 20% of cancers in Indian and sub-Saharan Africa are linked to HPV infection.[@R2]

While scientific and technological advances continue to improve health outcomes across the globe, these advances often take too long to reach poor and marginalised populations. Current technologies for cervical cancer provide a stark example of such disparities in access. Specifically, most technologies that are used successfully to prevent, screen and treat cervical cancer in high-income countries are out of reach to women in low and middle-income countries (LMIC).[@R3]

Chief among these is HPV vaccination, which has the potential to dramatically reduce the burden of cervical cancer in LMICs over the long term. International campaigns that have targeted girls aged 9--14 have achieved dramatic results in national scale-up.[@R4] Vaccination of young girls has become the highest priority for many national cervical cancer programmes in LMICs. At the same time, the fruit of this labour may not be fully realised until approximately 2050. Right now, an estimated 10% of healthy women around the world are already infected with HPV,[@R5] and without accelerated action to screen and treat precancerous lesions, deaths resulting from cervical cancer are estimated to increase to 443 000 per year by 2030.[@R6]

One method developed as a screening tool for use in low-income settings is visual inspection of the cervix with acetic acid (VIA). This is one of the options recommended by the WHO for cervical cancer screening in LMICs.[@R7] However, VIA has a low sensitivity, ranging from 21.9% to 73.6% in one multicountry study.[@R8] This means that many precancerous cervical lesions will not be identified with this method alone. In addition, VIA has a very low positive predictive value (PPV) in most populations. For example, VIA's PPV was only 6.2% in one study, which would indicate that in such a population more than 90% of women identified as needing treatment did not actually have precancerous lesions.[@R9] Moreover, the quality of VIA is very provider dependent, and there is a high degree of subjectivity in the assessment of the visual inspection,[@R10] which can further reduce the accuracy of the test in resource-constrained settings. User acceptability of VIA may also be limited due to low willingness on the part of patients to undergo the required pelvic exam,[@R11] which is a relatively resource-intensive procedure for health systems in LMICs.

In this context of VIA's limitations, HPV testing has become a staple of cervical cancer screening guidelines.[@R12] Many studies across a diverse range of countries and populations have been used to develop screening algorithms based on HPV testing. These algorithms are more capable of detecting precancerous cervical lesions than VIA.[@R8] Appropriately, WHO guidelines provide tiered screen and treat recommendations that consider resource availability and recommend, when possible, HPV testing for screening.[@R7] While WHO recommends screening at intervals of 5 years, emerging evidence suggests that HPV testing can elongate intervals between screenings greater than other methodologies, such as VIA and cytology. Strong evidence from a cohort of 20 000 patients at Kaiser Permanente demonstrated that a single negative HPV test can predict a very low risk of cervical intraepithelial neoplasia grade 3 or invasive cervical cancer (CIN3+) over 15 years.[@R16] There is still a risk of acquiring HPV later in life---although 75% of all infections are acquired by age 32---and epidemiology of infection differs between nations.[@R17] Still, this experience from the USA suggests that there could be great utility in using an HPV test in women over age 30 living in an LMIC. A negative result could confer up to 10 years of reassurance that the woman has a very low risk of CIN3+.[@R16]

Given the potential impact of HPV testing with screen and treat services for precancerous lesions in halting cervical cancer as a public health threat, this paper focuses on interventions. Both market-based and programmatic interventions can enable at-scale provisions in LMICs. This paper examines a selection of potential levers that could accelerate access to HPV testing, for both existing and new technologies. It also looks at potential innovations or approaches that may lower barriers to HPV testing with screen and treat programmes, such as increasing user acceptability, reducing price, standardising product preferences and integrating services into national cancer plans and the existing health infrastructure. Together, these interventions have the power to dramatically decrease cervical cancer incidence, morbidity and the number of deaths in LMICs.

Methods {#s2}
=======

This paper is built on experience, research and practice from a team of nine experts across three institutions. This collaboration first began at the UN Foundation Meeting for the WHO Programme to Eradicate Cervical Cancer, when members of the National Institutes of Health (NIH) and Bridge to Health Medical and Dental (BTH) began discussions with members of US Agency for International Development (USAID) around a model for integrating and accelerating services for cervical cancer.

An initial concept note was drafted by all parties, with a stakeholders meeting held at the NIH in October 2017. From there, the team mapped a seven-tiered approach to scaling up and expanding cervical cancer eradication strategies, dividing work based on federal mandates and specific experiences of agencies.

Specifically, USAID built on knowledge of product development, scaling services and integrated frameworks on success of past initiatives such as tuberculosis (TB), malaria and HIV. The NIH provided data on research and development around HPV testing and cervical cancer treatment devices. BTH provided insights and literature from experiences on the ground of integrated screen and treat programmes and HPV testing.

For HPV tests, one team member conducted a structured search of HPV test-producing companies. Each company was contacted individually for information.

Accelerate access to HPV testing through an end-to-end approach {#s3}
===============================================================

To increase access to HPV testing as a means of reducing morbidity and mortality from cervical cancer, it is critical to employ an 'end-to-end approach'. An 'end-to-end' approach encourages early planning for all aspects of new product introduction, as well as harmonising activities that have historically happened sequentially so they can be implemented in parallel and more quickly.[@R18] Traditionally, the approach involves evaluating four core aspects of introduction and scale-up, including user understanding and acceptability; manufacturing and distribution; clinical evidence needed to meet regulatory requirements; and finally, policy, advocacy and financing. Coordination, collaboration and integration underpin all these components as it is crucial to align diverse stakeholder interests, coordinate stakeholder activities and set a long-term vision and strategy.[@R19]

Beginning with the 'end in mind' for cervical cancer, we focus on sustainably implementing HPV testing, screening and treatment at scale in LMICs, where health systems are often overburdened and resources scarce. Stakeholder coordination plans for introduction and scale is often more challenging and possibly even more important in LMIC markets, as there may not be a single-for-profit company that takes the lead. By planning together with the end in mind, the diverse stakeholders needed for a successful introduction can facilitate healthy markets for the product or service, encourage faster and broader uptake, and accelerate the development of improved products---all ultimately generating better health outcomes more efficiently and quickly.[@R18] These levers include (1) increasing HPV test intervals to reduce HPV DNA test costs; (2) exploring market-shaping opportunities; (3) employing iterative user research methodologies like human-centred design (HCD); (4) target product profiles (TPP) for new HPV tests; (5) encouraging innovation around cervical cancer screen and treat programmes; (6) developing national cancer control plans; and (7) integrating cervical cancer screen and treat services into existing infrastructure. Each of these levers is described in the context of HPV testing and cervical cancer screen and treat programmes.

Increasing HPV test intervals reduces HPV DNA test costs {#s3-1}
--------------------------------------------------------

Various studies have demonstrated that screening strategies involving initial HPV testing can be more cost-effective under certain assumptions than strategies that are based on cytology or VIA.[@R21] Research by Goldie and colleagues modelled data to determine the cost of a single lifetime HPV test for women who screened positive using VIA or other cytological methods. Their data show that the cost of a single HPV test for these women is \$39/years of life saved.[@R23] Furthermore, while a single lifetime HPV test at age 35 has already demonstrated to be cost-effective compared with no screen, there is potential to lower the cost of HPV tests further. This can be achieved by lowering the price per HPV test kit. For example, as of 2018, the least expensive commercial HPV test kit price is \$5[@R24]; however, in many cases costs can reach as high as \$40 ([table 1](#T1){ref-type="table"}), compared with \$0.5--\$3 for VIA, and \$7--\$12 for cytology.[@R23]

###### 

Available HPV test options and details\*

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                            Company              Cost of machine\    Batch size†           Time to result†                     Sensitivity, specificity (%)
                                                                 price/test (US\$)                                                             
  ----------------------------------------- -------------------- ------------------- --------------------- ----------------------------------- ------------------------------
  Cervista HPV HR                           Hologic GEN-PROBE    Unknown             Unknown               6--7 hours                          100, 2

  APTIMA HPV                                Hologic GEN-PROBE    Unknown             100--250              Unknown                             97.6, 90.22

  Cobas HPV Test                            Roche                Unknown             8, 24, 48, 72 or 96   5 hours/94 samples                  97.3, 84.52

  Xpert HPV‡                                Cepheid              Unknown             96--160               1 hour                              84.8--96.9, 36.1--46.9

  Digene HC2 HPV DNA Test                   Qiagen               Unknown             88                    6--7 hours for 88 samples, manual   97.5, 84.42

  careHPV Test                              Qiagen               N/A\                80                    2.5 hours                           90.0, 84.22
                                                                 \$5                                                                           

  OncoE6 Cervical Test§                     Arbor Vita           \$1570 or less\     1--24+ per batch      2.5 hours, including sample prep    53--100; 98--99
                                                                 N/A                                                                           

  RealTime High-Risk HPV                    Abbott Molecular     Unknown             24--96                Unknown                             95.0, 87.22

  HPV Direct Flow Chip+ hybriSpot system¶   Master Diagnóstica   \$3500--\$30 000\   24                    3--4 hours                          100, 67
                                                                 \$25--\$40                                                                    

  PapilloCheck\*\*                          Greiner Bio-One      Unknown             12                    5 hours                             95.8, 96.7
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*All data acquired between December 2017 and March 2018 online through publicly available sources or through personal email communications with manufacturers.

†Pan American Health Organization (2016).[@R26]

‡Personal email communication with Cepheid, February 2018.

§Personal email communication with Arbor Vita, January 2018.

¶Personal email communication with Master Diagnóstica, February 2018.

\*\*Personal email communication with Greiner Bio-One, February 2018.

HPV, human papillomavirus; N/A, not applicable.

Explore market-shaping opportunities to improve efficiency of the HPV test market {#s3-2}
---------------------------------------------------------------------------------

Market shaping is focused on enhancing the many interactions of a well-functioning market to increase access to priority health interventions.[@R25] 'It can accelerate product access, enhance market stability, and increase last-mile availability as well as improve value for money in procurements and programmatic investments.' For example, the revolving fund at Pan American Health Organization[@R26] takes advantage of its bulk purchasing power to protect people against some of the world's worst disease, including polio, measles, and so on. To increase the affordability of HPV tests, partners can explore pooling procurement or coordinating orders to reduce the transaction costs associated with placing and responding to orders. By pooling procurement, a third party would consolidate orders for HPV tests across multiple buyers---reducing transaction costs for supply-side actors while providing greater demand visibility. Pooled procurement smooths out staggered ordering and production timelines. Furthermore, it streamlines supplier engagement with a single point of contact. To redistribute risks between suppliers and buyers, risk sharing interventions like advance market commitments or volume guarantees could incentivise suppliers to invest in developing and delivering new HPV tests. Lastly, lowering transaction costs, increasing market information and appropriately distributing risk between suppliers and buyers could increase affordability and availability of HPV tests.

To further reduce the costs of HPV tests, institutions are exploring batch testing. By simultaneously assessing multiple samples, batching can reduce the cost per HPV test, which distributes the costs of equipment, consumables, maintenance and staff time over a larger volume of tests.[@R27] A number of manufacturers have created equipment that can run in batch or non-batch mode.

Employ iterative user research methodologies like HCD to develop contextually appropriate HPV tests and generate demand {#s3-3}
-----------------------------------------------------------------------------------------------------------------------

To increase uptake of HPV testing by end-users, iterative and immersive user research methods like HCD can be incorporated into product development and demand generation programmes for HPV testing. HCD prioritises collaborating with those most affected by a new intervention or programme. This understanding then informs the rapid and iterative development of prototypes and eventually solutions.

HCD methods can encourage HPV testing. For example, using HCD, the acceptability of women collecting their own sample for HPV DNA tests was assessed. The research demonstrated that self-collection was acceptable.[@R28] Furthermore, when these samples were processed with a PCR-based HPV test, their quality compares with those obtained from physician-collected samples.[@R29] In this study, samples were collected by patients using ready-made test kits after instruction from a community health worker (CHW). The samples were returned either the same or next day to the CHW for processing.[@R29] Additional details regarding HPV testing and these options are presented in [table 1](#T1){ref-type="table"}. HCD research provides insights and solutions into how to leverage self-testing to help nations achieve HPV test coverage targets.

TPPs for new HPV tests {#s3-4}
----------------------

TPPs are commonly referenced in the aid and development communities. A TPP defines a set of product attributes that could include information such as how the product will be used, by or for whom the product will be used, and the minimum and ideal performance criteria. TPPs could also include criteria such as product presentation, product storage and shelf life. TPPs communicate requirements for products that are not currently on the market. As such, TPPs provide market signals, guide the industry and develop products that meet the needs of the community.[@R30] In 2014, the WHO released a TPP for HPV testing.[@R32] The WHO also prequalified careHPV and Gene Xpert HPV as in vitro HPV diagnostic tests.[@R33] To manufacturers, these two steps signal marketplace confidence and indicate a need for new HPV tests. As more information emerges about HPV testing in LMICs, TPPs could be amended to include other important market and user research.

Encourage innovation around cervical cancer screen and treat products {#s3-5}
---------------------------------------------------------------------

As mentioned above, many millions of women will not be vaccinated against HPV, leaving a generation or more in need of innovative solutions to screen and treat for precancerous cervical lesions. Innovations in this arena have the potential to revolutionise availability, cost and user acceptability of treatment.

The WHO recommends two options for treating precancerous cervical lesions as part of screen and treat programmes: loop electrosurgical excision procedure (LEEP) and cryotherapy.[@R31] Techniques such as thermocoagulation, also called cold coagulation, are being revisited as potential treatment options to replace cryotherapy in low-resource settings.[@R34]

While effective, these technologies typically require complex infrastructure with expensive materials and some level of trained health provider, in particular around LEEP. However, an exciting addition to treatment options are more novel and portable thermocoagulation and gas-less cryotherapy devices.[@R36] These devices can be brought directly into the field and used on a per-patient basis, while linked with a comprehensive screen and treat campaign. This method has proven particularly useful as part of outreach services for rural, isolated communities. While further practical evidence is required to prove that this strategy works at scale, integration of these services on a smaller scale has ensured that cases are detected and treated in the same visit. For example, BTH in partnership with the County Government of Kisumu (CGK) and Africa Cancer Foundation have successfully pilot tested a portable thermocoagulator, upgrading the County Health Department from 'See' to 'See and Treat'. See [figure 1](#F1){ref-type="fig"} for BTH and CGK staff using the device. Facilities implementing this strategy should ensure that quality assurance systems are in place to prevent harm, such as pain or bleeding, which could occur through ablation of invasive cancers.

![A Canadian family physician teaching a Kenyan obstetrician-gynaecologist how to use a portable thermocoagulation device.](fmch-2019-000182f01){#F1}

The cost of any novel therapy is always considered. Work by Maza and colleagues documents that most widely used cryotherapy devices have an estimated cost between \$1700 and \$2000, with additional tips costing approximately \$200 each. Additionally, the required gas and related costs can range from \$13 to \$38 per treatment. These costs are slightly less than the WiSAP Cold-Coagulator. The LMIC customised device costs about \$2500. Among other advantages, the WiSAP tip can be sterilised with high-level disinfection; it does not require autoclave.[@R36]

Although effective, current treatment options for precancerous lesions are invasive, and can be expensive in terms of infrastructure, personnel and equipment required. An alternative could be affordable and effective non-surgical treatments. Several innovative, non-surgical treatments are being developed by the National Cancer Institute in the form of therapeutic vaccines, antivirals and topical applications.[@R35] The goal of therapeutic vaccines is to elicit an immune response by targeting E6 and E7 antigens. As of 2018, there are therapeutic vaccine candidates in phase III clinical trials.[@R35] Additionally, there are several ongoing studies on the use of antiviral drugs to target HPV, as well as adoptive T-cell therapy. None have advanced to phase III clinical trials and have shown limited effectiveness to HPV.[@R35]

Finally, in order to treat precancerous lesions HPV infection must be rapidly diagnosed. There are different efforts to develop paper-based HPV screening technologies; immunoassays constructed on nitrocellulose lateral flow strips. These efforts are far from complete, but a test is currently available to determine HPV vaccination status.[@R38] This example illustrates an exciting potential innovation that will bring a cost-effective test directly to the field.

Develop comprehensive national cancer control plans that include HPV testing {#s3-6}
----------------------------------------------------------------------------

To ensure alignment with the Ministry of Health, or equivalent, priorities and engender political commitment, HPV testing should be introduced as part of a comprehensive national cancer control plan, such as in Suriname.[@R39] An important first step would be a barrier assessment identifying challenges to scale-up of cervical cancer services, categorised by level of urgency. This assessment would then inform the prioritisation of interventions, which could include increasing the capacity or staffing of health providers. Additionally, the assessment could be used to develop an algorithm for referral and care or to integrate HPV testing into existing health services so that the health system can enable more women to receive the proper follow-up treatment. Moreover, the control plan can consider a strategy for triaging patients to prioritise treatment, depending on the availability of a secondary test (eg, VIA, cytology or a different HPV test) and the feasibility of treatment.[@R40] Current research suggests that VIA may not be an effective or cost-effective method of triage, but additional research is required to determine preferred triage strategies.[@R21]

Integrate cervical cancer screen and treat services into the existing infrastructure of health services {#s3-7}
-------------------------------------------------------------------------------------------------------

As discussed previously, while HPV testing can revolutionise cervical cancer screening, the treatment component of screen and treat is critical in the case of a positive screen. Without same-day treatment, many women with positive screen results may not be able to return for a follow-up visit and thus never receive appropriate treatment.[@R22]

To ease barriers to accessing relatively new forms of care, such as HPV testing and cervical cancer screen and treat services, integration into existing vertical disease programmes can be a powerful tool. Vertical programmes that currently provide diagnosis and treatment services for HIV/AIDS, TB, malaria and family planning all offer a channel with existing clinics to reach women at risk of cervical cancer. When integrated into functional clinics, screen and treat services can result in fewer cases being lost to follow-up and a lower number of invalid HPV tests; they can also eliminate the need for additional refrigeration and transportation of specimens. These benefits are seen as a result of the testing being available directly in the field, with reduced challenges in transportation, storage and other realities of managing pathology in a low-resource setting. Collectively, these advantages can significantly increase the feasibility of implementing a national cervical cancer screening and treatment programme.

Women living with HIV are estimated to have a fourfold to fivefold higher likelihood of cervical cancer incidence.[@R42] In response, the US President's Emergency Plan for AIDS Relief has partnered with many organisations to integrate cervical cancer screening and treatment into existing HIV platforms with initial success at a small scale.[@R44] Furthermore, effective integration of cervical cancer screenings has been shown to increase uptake of reproductive health services.[@R45]

A practical example is the Cervical Cancer Prevention Program in Zambia, which circumvented the heavy infrastructure issue by piggybacking on existing HIV prevention and treatment programmes to share equipment and clinic locations. This integration of services reduced the time required to implement cervical cancer screen and treat services, while also increasing participation in regular gynaecological exams.[@R46] Further, these synergies opened up resources to address other barriers, such as enabling the purchase of LEEP equipment to treat precancerous cervical lesions. Another example of successful integration is the Cervical Cancer Screening and Preventive Therapy programme, which operated in Uganda, Tanzania, Nigeria and Kenya, and reported increased uptake of both cervical cancer screening and voluntary family planning interventions when the two were offered in tandem.[@R45]

Integration of programmes is a promising but relatively new strategy for promoting cervical cancer screening and treatment. The examples above leveraged VIA-based screening, but an integration strategy can be applied to HPV-based screening too. For HPV-based screening, integration would be most straightforward at facilities that already use a screening platform for one disease, such as Gene Xpert for TB, because HPV test cartridges fit into the same machine. To date, the examples above have not yet scaled to achieve high-coverage screening rates. Going forward, it may be worthwhile to integrate cervical cancer services with multiple existing programmes thereby overcoming any incompatibilities that prevent high screening rates.

Conclusion {#s4}
==========

This paper applied an end-to-end approach to highlight a series of levers that could potentially accelerate access to HPV testing and screen and treat services. These levers included exploring global market-shaping opportunities to improve the market efficiency of HPV tests, employing iterative user research methodologies like HCD to develop new or improved HPV tests, aligning on TPPs for new HPV tests, encouraging innovation, developing national cancer control plans that include HPV testing, and integrating cervical cancer screen and treat services into existing infrastructure.

End-to-end planning can help align and coordinate diverse stakeholders across activities and facilitate healthy markets---ultimately, more successfully delivering cervical cancer technologies and interventions in LMICs.

Effective and efficient planning ensures that tailored products and programmes reach their target populations across a country. Now is the time for countries to identify and invest in regionally, cost-effective technologies that are integrated into programmes that can be feasibly scaled. Together, we can protect our next generation of women from cervical cancer.
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